US2021301037A1PendingUtilityA1

Antibodies Targeted to Fungal Cell Wall Polysaccharides

70
Assignee: WELLSTAT VACCINES LLCPriority: Mar 12, 2013Filed: Mar 23, 2021Published: Sep 30, 2021
Est. expiryMar 12, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61K 47/6415C07K 16/14A61K 2039/6031A61K 39/385A61K 2039/627A61K 47/646A61P 31/10A61K 2039/6037A61K 39/0002C08B 37/003
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH—R]n-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of protecting a mammalian subject against a fungal infection, comprising administering to the subject an isolated antibody in an amount effective to protect the subject against the fungal infection,
 wherein the antibody is specific to a compound comprising one or more polysaccharide moieties, each independently represented by the formula β(1→4)-[GlcNH-R]n-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, R is H or an acetyl group, and the one or more polysaccharide moieties are chitin/chitosan mixed polymers.   
     
     
         2 . The method of  claim 1 , wherein n is a positive integer from 3 to 100. 
     
     
         3 . The method of  claim 2 , wherein n is a positive integer from 6 to 50.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.